Nonvascularized human skin chronic allograft rejection.
accommodation
alloantibody
clinical research/practice
ethics and public policy
organ transplantation in general
pathology/histopathology
rejection: antibody-mediated (ABMR)
surgical technique
tolerance
vascularized composite and reconstructive transplantation
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
09
01
2019
revised:
16
07
2019
accepted:
19
07
2019
pubmed:
26
7
2019
medline:
12
9
2020
entrez:
26
7
2019
Statut:
ppublish
Résumé
A 65-year-old man had extensive burns of the lower legs in 1991, at the age of 40 years. He was treated by nonvascularized and de-epithelialized, allogeneic split-thickness skin allograft and cyclosporine monotherapy for 2 months. Ulcers developed between 10 and 25 years after transplantation and a surgical debridement on the lower extremities was required. Analyses of the removed tissue allografts showed chronic antibody-mediated and cellular rejection with extensive and dense fibrosis, and diffuse capillary C4d deposits. An anti-DRB1*08:01, donor-specific antibody was present. A unique clinical condition with late immunopathological features of human skin chronic allograft rejection is reported.
Identifiants
pubmed: 31344327
doi: 10.1111/ajt.15542
pii: S1600-6135(22)09311-X
doi:
Substances chimiques
Isoantibodies
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3191-3196Informations de copyright
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Gibson T, Medawar PB. The fate of skin homografts in man. J Anat. 1943;77(Pt 4):299-310 294.
Chandraker A, Arscott R, Murphy GF, et al. The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotransplant. Am J Transplant. 2014;14(6):1446-1452.
Horner BM, Randolph MA, Huang CA, Butler PE. Skin tolerance: in search of the Holy Grail. Transpl Int. 2008;21(2):101-112.
Hoffman DK, Sibley RK, Korman JM, Press BH. Light microscopic and immunohistochemical features in serial biopsies of epidermal versus dermal allografts. Ann Plastic Surg. 1994;33(3):295-299.
Swearingen B, Ravindra K, Xu H, Wu S, Breidenbach WC, Ildstad ST. Science of composite tissue allotransplantation. Transplantation. 2008;86(5):627-635.
Hewitt CW, Black KS, Aguinaldo AM, Achauer BM, Howard EB. Cyclosporine and skin allografts for the treatment of thermal injury. I. Extensive graft survival with low-level long-term administration and prolongation in a rat burn model. Transplantation. 1988;45(1):8-12.
Zhang R. Donor-specific antibodies in kidney transplant recipients. Clin J Am Soc Nephrol. 2018;13(1):182-192.
Roux A, Levine DJ, Zeevi A, et al. Banff Lung Report: current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR). Am J Transplant. 2019;19:21-31.
Petit F, Minns AB, Dubernard JM, Hettiaratchy S, Lee WP. Composite tissue allotransplantation and reconstructive surgery: first clinical applications. Ann Surg. 2003;237(1):19-25.
Cendales LC, Kanitakis J, Schneeberger S, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant. 2008;8(7):1396-1400.
Atiyeh BS, Costagliola M. Cultured epithelial autograft (CEA) in burn treatment: three decades later. Burns. 2007;33(4):405-413.
Saffle JR. Closure of the excised burn wound: temporary skin substitutes. Clin Plast Surg. 2009;36(4):627-641.
Krupp S, Wiesner L, Krstic R, Pescia G, Winistorfer B. Mid-term results with cultured epidermal autografts, allogenic skin transplants and cyclosporin A medication. Burns. 1994;20(1):15-20.
Achauer BM, Hewitt CW, Black KS, et al. Long-term skin allograft survival after short-term cyclosporin treatment in a patient with massive burns. Lancet. 1986;1(8471):14-15.
Chehade H, Rotman S, Matter M, Girardin E, Aubert V, Pascual M. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. Pediatrics. 2015;135(2):e551-e555.
Yerly P, Rotman S, Nobile A, et al. Time-dependent specificity of immunopathologic (C4d-CD68) and histologic criteria of antibody-mediated rejection for donor-specific antibodies and allograft dysfunction in heart transplantation. Transplantation. 2015;99(3):586-593.
Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272-283.
Salvade I, Aubert V, Venetz JP, et al. Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation. Hum Immunol. 2016;77(6):483-489.
Morelon E, Petruzzo P, Kanitakis J. Chronic rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant. 2018;23(5):582-591.
Morelon E, Petruzzo P, Kanitakis J, et al. Face transplantation: partial graft loss of the first case 10 years later. Am J Transplant. 2017;17(7):1935-1940.
Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant. 2013;13(12):3114-3122.
Kanitakis J, Karayannopoulou G, Lanzetta M, Petruzzo P. Graft vasculopathy in the skin of a human hand allograft: implications for diagnosis of rejection of vascularized composite allografts. Transpl Int. 2014;27(11):e118-e123.
Hogenes MCH, Te Boome LCJ, van der Valk DC, et al. Clinical versus histological grading in the assessment of cutaneous graft versus host disease. Eur J Med Res. 2019;24(1):19.
Prieto-Torres L, Boggio F, Gruber-Wackernagel A, Cerroni L. Nodular sclerodermatous chronic cutaneous Graft-Versus-Host Disease (GvHD): a new clinicopathological variant of cutaneous sclerodermatous gvhd resembling nodular/keloidal scleroderma. Am J Dermatopathol. 2017;39(12):910-913.